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Background: Evidence indicates that early life stress (ELS) can induce persistent changes in
the hypothalamic-pituitary-adrenal (HPA) axis to respond to stress in the adult life that leads
to depression. These appear to be related to the impairment of HPA hormones through
binding to glucocorticoid (GR) and mineralocorticoid receptors (MR). The aim of this study
was to evaluate the impact of ELS in HPA axis response to challenges with GR and MR
agonists in depressed patients.
Methods: We included 30 subjects, 20 patients with current major depression (HAM-
D21≥17). Patients were recruited into two groups according to ELS history assessed
by the Childhood Trauma Questionnaire (CTQ). The cortisol measures in the saliva and
plasma were evaluated after using (at 10:00 p.m.) placebo, fludrocortisone (MR agonist),
or dexamethasone (GR agonist).
Results: Depressed patients showed a significantly lower salivary cortisol upon waking
after placebo compared with controls. Moreover, cortisol awakening responses (CAR) after
MR agonist were found to be lower in depressed patients than in controls.With CTQ scores,
HAM-D21, body mass index and CAR after placebo, GR agonist, MR agonist we found in a
Linear Regression model that depressive patients with ELS (p=0.028) show differences
between placebo vs. MR agonist (R=0.51; p<0.05) but not after GR agonist; in depres-
sive patients, without ELS the data show differences between placebo vs. MR agonist
(R=0.69; p<0.05); but now as well placebo vs. GR agonist (R=0.53; p<0.05).
Conclusion: Our findings indicate that MR activity is impaired in depressed patients
compared with controls. Furthermore, in spite of the previous limitations described, in
depressed patients with ELS, there was suppression by MR agonist, indicating that patients
with ELS are sensitive to MR agonists. In contrast with depressed patients without ELS,
we find suppression after both MR and GR agonist. These data suggested that in ELS an
imbalance exists between MR and GR with MR dysfunction.
Keywords: early life stress, hypothalamic-pituitary-adrenal, cortisol, glucocorticoid receptors, mineralocorticoid
receptors, depression
INTRODUCTION
Stressful life events play an important role in the pathogenesis
of depressive disorders and are well established as acute triggers
of psychiatric illness (1). According to the literature, early life
stress (ELS), such as child abuse, neglect, or parental loss, has
been associated with significant increase in the risk of developing
depression in adulthood (2–5). Recent studies show that ELS can
also influence the clinical course and a poorer treatment outcome
of depression (6, 7). Child abuse and neglect can be perceived
as agents for neurodevelopment disturbance and, depending on
when it occurs, can cause neurological “scars” in some structures,
which could make some individuals vulnerable to certain types of
psychopathology, especially depression (4, 8, 9).
Considerable evidence suggests that this vulnerability for devel-
oping psychiatric disorders is associated with changes in neu-
robiological systems related to stress regulation. Abnormalities
in hypothalamic-pituitary-adrenal (HPA) axis have been widely
described in the literature, in people experiencing mood disorder
(10–12). Moreover, studies indicate that stress in early phases of
development can induce persistent changes in the ability of the
HPA axis to respond to stress in the adult life, and that mechanism
can lead to a raised susceptibility to depression (13, 14). How-
ever, despite strong evidence in the literature suggesting that ELS
is associated with abnormalities in HPA axis that leads to depres-
sion, there is no clear consensus whether the ELS leads to hyper-
or hypo-activation of this axis (15).
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In this sense, one aspect of the function of HPA axis that
recently received particular attention for the understanding of
HPA axis disturbances is the measurement of salivary corti-
sol in response to awakening (16–18). The cortisol awakening
responses (CAR) are the rapid increase in cortisol levels that
peaks approximately 30–45 min after awakening in the morn-
ing (16, 18). CAR is considered a reliable measure of basal HPA
axis activity and represents the acute response of the HPA axis
to awakening (19). Although in recent decades this phenome-
non has been studied mainly in healthy populations, recently,
some studies have described altered CAR in psychiatric disor-
ders, such as depression (20–24). However, the findings related
to depression and CAR are heterogeneous. While some studies
found an increased CAR in depressed patients (21, 24), other stud-
ies have reported a blunted CAR in depression (22). In addition,
some studies have demonstrated that increased CAR can be an
important risk factor for the development of depression in adults
(25, 26).
One of the mechanisms thought to be involved in these abnor-
malities is the impaired feedback inhibition of the HPA axis by the
circulating glucocorticoids (27). Hypothalamic-pituitary activity
leads to the production of glucocorticoids from the adrenal cor-
tex. In turn, glucocorticoids mediate their actions, including a
feedback inhibition, through two distinct intracellular receptor
subtypes: the type I or mineralocorticoid receptor (MR) and the
type II or glucocorticoid receptor (GR). These receptors differ
in their affinity for glucocorticoids, with MR demonstrating the
highest affinity for cortisol and GR demonstrating lowest affinity
for cortisol (28–31).
Thus, the dysfunction of MR and GR has been implicated in
stress-related psychiatric diseases such as depression (32–36). In
this sense, several studies have been published since the 70s with
dexamethasone suppression test (DST), a synthetic glucocorti-
coid that binds preferentially to GR (15, 37–40). Most studies
have demonstrated that severely depressed patients often show
non-suppression and impaired feedback inhibition by dexam-
ethasone, which is indicative for dysfunction of corticosteroid
receptors, especially GR (34, 41–43). However, due to low sen-
sitivity of the DST (20–50%) to distinguish between patients
with major depression and patients with other psychiatric dis-
orders or healthy subjects (39, 44), Holsboer et al. have devel-
oped a more sensitive neuroendocrine test (45, 46) that combines
the DST and the corticotropin-releasing hormone (CRH) stim-
ulation test, and it is called the dexamethasone/corticotrophin-
releasing hormone (Dex/CRH) challenge test. A suppressive
test using another synthetic glucocorticoid, prednisolone, has
recently been developed. Current evidences suggest that the pred-
nisolone suppression test (PST), in contrast to the DST and the
Dex/CRH test, probes both the MR and the GR and hence pro-
vides a more valid test of the HPA axis in depression (33, 34,
40, 47).
On the other hand, some studies have been published using
challenges that assess, preferentially, MR function in depression
using fludrocortisone (MR agonist) or spironolactone (MR antag-
onist), but these studies are still restricted and revealed unclear
results. In this sense, Buckley et al. (48) evaluated the acute effects
of fludrocortisone (0.5 mg) on nocturnal HPA axis activity in
healthy subjects, finding that it is able to inhibit nocturnal activ-
ity of the HPA axis, showing significant clinical implications for
the treatment of insomnia and depression (48). In a recent study,
Lembke et al. (49) reported that patients with psychotic major
depression (PMD) have diminished feedback inhibition of HPA
axis in response to fludrocortisone compared to healthy control
subjects (49). Otte et al. (50) examined the role of MR in the
response to antidepressants through stimulation and blockade
of MR and found decreased plasma cortisol levels in depressed
patients treated with fludrocortisone as adjunct to escitalopram
and the stimulation of MR with fludrocortisone accelerated the
treatment response. Furthermore, the combination of spirono-
lactone and escitalopram increased plasma cortisol levels during
treatment (50). Still regarding the evaluation of blockade of MR
with spironolactone, both studies by Heuser et al. (51) in healthy
controls and Young et al. (52) in depressive patients showed
a significant increase in cortisol levels in subjects treated with
spironolactone.
Therefore, these data have lead to the hypothesis that an imbal-
ance in MR and GR functioning may be a risk factor for depression
(29). Moreover, results from studies examining the relationship
between ELS and HPA axis indicate that ELS, in combination with
the genetic background, seems to sensitize certain circuits in the
brain and leads to persistent alterations in reactivity and sensitiza-
tion of the HPA axis to subsequent stress, as reflected in an altered
MR/GR balance that contributes to the risk for depression (53–
56). In this area, the majority of studies is restricted to assessment
of GR by the traditional DST and Dex/CRH test (8, 24, 55, 57–59)
and only a few recent studies used the PST that assesses both GR
and MR (34, 36, 47, 60). Moreover, according to our knowledge
to date, no studies have been published that specifically evalu-
ate the functioning of MR in depressive patients with ELS with
neuroendocrine challenges.
Finally, regarding the assessment of MR and GR receptors
through the CAR in depressed patients, studies are still restricted
and as well as other studies in this area are limited to assessment of
GR with DST (61). Thus, more studies are needed, with tests that
assess both GR and MR receptors through the CAR, for a better
understanding of the role of the ELS on MR function in depres-
sive patients. Therefore, we hypothesize that the ELS results in a
persistent dysfunction of HPA axis and GR/MR receptors, leading
to MR malfunction, in adult depressive patients. Based on these
data, in the present study, we evaluated the impact of ELS in HPA
axis response to challenges with GR and MR agonist in depressed
patients.
MATERIALS AND METHODS
STUDY DESIGN
The study used a single-blind, non-randomized, placebo-
controlled, repeated-measure design. Before each study day, the
subjects were instructed to take one capsule (at 10:00 p.m.),
containing placebo, dexamethasone (0.5 mg), or fludrocortisone
(0.5 mg). No alcohol, coffee, tea, or meals were allowed after each
capsule. Salivary samples were collected at 10:00 p.m. right after
drug administration, the following day immediately upon awak-
ening, 30 min later, 60 min later, and before plasma collection at
9:00 a.m.
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The study protocols were all approved by the Research Ethics
Committee of the General Clinical Hospital, Faculty of Medicine
of Ribeirao Preto, University of Sao Paulo.
PARTICIPANTS
A total of 30 subjects, aged 18–65 years, including 20 depressed
patients and 10 healthy controls participated in the study. Written
informed consent was obtained from all subjects.
We examined depressed inpatients at the Day Hospital Unit
of the General Clinical Hospital. Patients were included in this
study if they had a diagnosis of depressive episode according to
DSM-IV criteria (62) and a score of 17 or more in the Hamilton
Depression Rating Scale [HAM-D21; (63)]. For convenient reasons
it was not possible to test the patients in a drug-free state. All 20
patients were taking medication during the assessment. Thirteen
patients were taking benzodiazepines (diazepam and clonazepam);
12 SSRIs (fluoxetine and sertraline); 9 antipsychotics (chlorpro-
mazine, haloperidol, risperidone, quetiapine, and olanzapine);
6 tricyclics (imipramine, amitriptyline, clomipramine, and nor-
triptyline); 6 other antidepressants (bupropion and venlafaxine);
4 mood stabilizers (lithium, lamotrigine, topiramate, and oxcar-
bazepine); and 3 other drugs (promethazine). Exclusion criteria
for the patient group were a history of hypersensitivity to corti-
costeroids or steroid use, heavy smoking (more than 25 cigarettes a
day), a viral illness during the preceding 2 weeks, pregnancy or lac-
tation, alcohol dependence, and significant physical illness (severe
allergy, autoimmune disease, hypertension, malignancy, or hema-
tological, endocrine, pulmonary, renal, hepatic, gastrointestinal,
or neurological disease). We also excluded patients with current
alcohol or drug abuse/dependence, mental retardation, psychotic
symptoms unrelated to their depressive disorder, or an organic
cause for their depression.
On the basis of positive history of ELS, depressed patients were
divided into two groups. The first included those with ELS and the
second included those without ELS . We included in the group with
ELS only the patients with scores moderate to severe or severe to
extreme according to the Childhood Trauma Questionnaire [CTQ;
(64)]. Among the 20 depressed patients evaluated, 13 (65%) had
experienced some form of ELS and 7 (35%) had no history of ELS.
The healthy controls, matched as a group to the depressed
patients according to gender and body mass index (BMI; within
a range of ±5 kg/m2), were recruited from hospital staff, stu-
dents, and the local community via public advertisement. The
control group participants were physically healthy on the basis
of a complete medical history and examination, were not tak-
ing any psychotropic medication, were not taking any hormonal
medication (including oral contraceptives), and had no history
of hypersensitivity to corticosteroids. Healthy individuals were
excluded if they had a personal history or first-degree relative
history of a DSM-IV axis I disorder or history of ELS.
CLINICAL ASSESSMENTS
Demographic, clinical, and psychosocial data were obtained from
medical charts and semi-structured clinical interviews carried out
by researchers. All subjects were interviewed by a psychiatrist using
the Mini International Neuropsychiatric Interview [MINI; (65)],
version in Portuguese translated and adapted by Amorim (66)
for confirmation of the diagnosis of major depression. The MINI
is a brief structured interview designed to assess criteria for the
major axis I psychiatric disorders classified in DSM-IV and ICD-
10. The diagnostic assessment was conducted using the MINI
for DSM-IV diagnoses by two seniors psychiatrists (Mário Fran-
cisco Juruena; Cristiane von Werne Baes) trained and certified
to the use of the standardized interviews. The interviewers had
long-standing experience in the administration of standardized
interviews. For assessment of the severity of depression, partici-
pants were interviewed using the 21-item Hamilton Depression
Rating Scale [HAM-D21; (63)]. Patients were required to have a
score of at least 17 on the 21-item HAM-D for inclusion in this
study. We used a cut-off score of 17 or more in order to define a suf-
ficient level of depression ensuring the inclusion of patients with
moderate to severe clinical levels of depressive illness. The basis
for this was that this is a score generally used in treatment trials
in depression, and specifically equates to that used in STAR*D,
which used a 17-item HAM-D cut-off of 14, which is equivalent
to a cut-off of 16 on the 21-item HAM-D (67). However, there is
no consensus in the literature concerning a specific cut-off point
defining mild to moderate depression in the 21-item HAM-D.
Early life stress measures
The ELS was assessed using the CTQ (64). The CTQ is a retrospec-
tive self-report questionnaire that investigates history of abuse and
neglect during childhood and can be applied to adolescents (from
12 years) and adults where the responder assigns values of fre-
quency to 28 graduate assertive issues related to situations arising
in childhood. The CTQ evaluates five subtypes of ELS:
Emotional abuse: verbal assaults on a child’s sense of worth or
well-being or any humiliating or demeaning behavior directed
toward a child by an adult or older person;
Physical abuse: bodily assaults on a child by an adult or older
person that posed a risk of or resulted in injury;
Sexual abuse: sexual contact or conduct between a child younger
than 18 years of age and an adult or older person;
Emotional neglect: the failure of caretakers to meet children’s
basic emotional and psychological needs, including love, belong-
ing, nurturance, and support;
Physical neglect: the failure of caretakers to provide for a child’s
basic physical needs, including food, shelter, clothing, safety, and
health care (poor parental supervision was also included in this
definition if it placed children’s safety in jeopardy) (68).
The items are rated on a Likert scale ranging from 1 (never)
to 5 (very often). Furthermore, the scores range from 5 to 25 for
each type of ELS. The instrument also contains a subscale of min-
imization/denial to identify individuals responding in a socially
desirable manner, and a cut point for ELS was defined as when
one of these experiences before the age of 18 reached a degree of
at least moderate to severe, or severe to extreme according to clas-
sification of CTQ. The version in Portuguese was translated and
adapted by Grassi-Oliveira et al. (69).
ENDOCRINE ASSESSMENTS
The suppression tests were administered shortly after study admis-
sion for patients and controls (range 5–10 days). On day 1, the
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subjects were instructed to take one capsule (at 10:00 p.m.) con-
taining placebo, followed by assessment of cortisol. Forty-eight
hours after the administration of placebo (day 4) subjects took the
second capsule (at 10:00 p.m.) containing fludrocortisone 0.5 mg
and they repeated the assessment of cortisol. On day 7, 48 h after
the administration of fludrocortisone, they took the third capsule
(at 10:00 p.m.) containing dexamethasone 0.5 mg and repeated
the assessment of cortisol.
Cortisol assessment consists of analysis of five salivary sam-
ples and one plasma sample. Salivary samples were collected using
Salivettes (Sarstedt, Germany) that contained an untreated cotton
swab. Subjects were instructed to collect the first Salivette at 10:00
p.m. after drug administration and not to drink alcohol, exercise,
or engage in stressful activities right after drug intake. Participants
were also instructed not to smoke,drink caffeine, eat, or brush their
teeth in the 60 min prior to salivary collection. This instruction
was given verbally accompanying the sampling tubes. New sali-
vary samples were collected immediately upon awakening, 30 and
60 min later; these three samples were used to determine the CAR.
Another salivary sample was collected at 9:00 a.m. before collection
of plasma cortisol. Blood and salivary samples were immediately
centrifuged at 3000g for 10 min, aliquoted, and stored at −40°C
and analyzed at the Endocrinology Laboratory of the General Clin-
ical Hospital, Faculty of Medicine of Ribeirao Preto, University
of Sao Paulo, by RIA (70). Detection limits and the intra-assay
and inter-assay coefficients of variation were: 1.68 nmol/L, 2.1 and
9.3% for salivary cortisol and 33.10 nmol/L, 2.8 and 10.4% for
plasma cortisol.
STATISTICAL ANALYSIS
All values are presented as mean and standard error of the mean.
The main parameter of CAR used in this study was the area under
the curve with respect to ground (AUCg; nmol× h/L). AUCg
was calculated according to the trapezoidal method described by
Pruessner et al. (71), which considers the distance of individ-
ual measurements to the baseline and represents an estimate of
total cortisol secretion within the first hour after awakening, as
demonstrated below (Figure 1):
FIGURE 1 | Formula for calculation of area under the curve with respect
to ground (AUCg). Adapted from Pruessner et al. (71). Note: m denotes
single measurements; t denotes time interval between measurements.
Chi-squared tests with Bonferroni corrected post hoc tests were
used to assess the significance for dichotomous variables. Contin-
uous variables were calculated by t -tests to compare differences
between depressed patients and control group and by one-way
analysis of variance (ANOVA) with Tukey corrected post hoc tests
for comparisons among patients with ELS, without ELS, and con-
trols. We used a general linear model (GLM) analysis for repeated
measures to examine both between-group differences (depressed
patients with ELS vs. without ELS vs. controls) and within-group
differences (placebo vs. fludrocortisone vs. dexamethasone) in
salivary cortisol at 10:00 p.m., immediately upon awakening, 30
and 60 min later and 9:00 a.m. Further analyses were conducted
using one-way ANOVA with Tukey corrected post hoc tests for a
comparison of mean CAR levels between placebo vs. fludrocor-
tisone vs. dexamethasone. Pearson’s test was used to examine the
correlations between CTQ scores and plasma cortisol.
The main objective of the present study was to evaluate the
impact of the severity of CTQ on, MR and GR in depressive
patients with and without ELS for which a multiple regression
analysis was conducted. Therefore, we have controlled some mea-
sures as depression scores (HAM-D), and BMI and use CTQ scores
as continuous measures correlating with CAR AUC (nmol× h/L)
after placebo vs. fludrocortisone vs. dexamethasone. All analyses
were conducted using the Statistical Package for the Social Sci-
ences, SPSS for Windows, release 15.0. A value of p< 0.05 was
considered statistically significant.
RESULTS
CLINICAL ASSESSMENTS
Depressed patients and controls did not differ significantly in gen-
der (X 2= 1.87; df= 1.0; p= 0.17) and BMI (t = 0.47; df= 26.0;
p= 0.64). Patients were significantly older than controls (t = 3.2;
df= 27.02; p= 0.003), mean age was 38.8 (±2.2) years in patients
and 29.4 (±1.8) years in controls. Among the patients, 11 (55%)
had a personality disorder, 17 (85%) had attempted suicide, and
18 (90%) had a positive family history of psychiatric disorders.
According to CTQ, more than half of the patient group (13/20;
65%) had experienced some subtype of ELS: specifically, 11 had
experienced emotional abuse, 10 reported physical neglect, 9
reported emotional neglect, 9 had experienced physical abuse,
and 7 had experienced sexual abuse. Furthermore, regarding the
amount of subtypes experienced by patients with ELS, most of
them (92.4%) reported having experienced two to five subtypes of
ELS. By definition, depressed patients with ELS had higher mean
CTQ scores than depressed patients without ELS (p< 0.001) and
controls (p< 0.001), mean CTQ total score was 74.0 (±5.1) in
depressed patients with ELS, 38.1 (±1.0) in depressed patients
without ELS, and 29.6 (±2.0) in controls. There were no differ-
ences in mean CTQ scores between depressed patients without ELS
and controls (p= 0.38). In addition, patients with ELS had sig-
nificantly higher scores than depressed patients without ELS and
controls in all CTQ subscales of abuse and neglect. There were no
differences between patients groups with or without ELS in gender,
age, and BMI. The groups differed significantly regarding the diag-
nosis of axis I psychiatric disorders (X 2= 4.12; df= 1.0; p= 0.04).
In the group of patients with ELS 100% (13/13) of the sample had
unipolar depression; on the other hand, in the group without ELS
almost 30% (2/7) of the sample had bipolar depression. Patients
with or without ELS showed no significant differences in the other
demographic and clinical variables (Table 1).
ENDOCRINE ASSESSMENTS
When comparing depressed patients vs. healthy controls, patients
showed a significantly lower salivary cortisol than control subjects
upon waking after placebo (t =−2.2; df= 28.0; p= 0.03). Mean
cortisol upon waking was 23.6 (±3.6) nmol/L in patients and 36.3
(±3.7) nmol/L in controls.
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Table 1 | Demographic and clinical features of depressed patients with or without early life stress.
With early life stress n=13 (65%) Without early life stress n=7 (35%) P
Gender, n (%) 0.79
Female 10 (76.9) 5 (71.4)
Male 3 (23.1) 2 (28.6)
Age, years (±SEM) 39.5 (±2.7) 37.4 (±4.3) 0.67
BMI, Kg/m2(±SEM) 29.2 (±2.0) 25.4 (±2.3) 0.24
Ethnicity, n (%) 0.59
Caucasian/white 7 (53.8) 5 (71.4)
Mulatto/mixed race 3 (23.1) 2 (28.6)
Black 2 (15.4) 0 (0)
Asian 1 (7.7) 0 (0)
Education, n (%) 0.68
≤4 years 2(15.4) 2 (28.6)
5–8 years 1 (7.7) 1 (14.3)
9–11 years 5 (38.5) 1 (14.3)
≥11 years 5 (38.5) 3 (42.9)
Marital status, n (%) 0.40
Never-married 4 (30.8) 2 (28.6)
Married 7 (53.8) 4 (57.1)
Separated/divorced 2 (15.4) 1 (14.3)
Employment status, n (%) 0,64
Employed 1 (7.7) 1 (14.3)
Unemployed 12 (92.3) 6 (85.7)
Smokers, n (%) 4 (30.8) 2 (28.6) 0.92
Clinical disease, n (%) 6 (46.2) 4 (57.1) 0.64
Axis I psychiatric disorders, n (%) 0.04
Unipolar depression 13 (100) 5 (71.4)
Bipolar depression 0 (0) 2 (28.6)
Axis II psychiatric disorders, n (%) 8 (61.5) 3 (42.9) 0.42
Positive family history, n (%) 12 (92.3) 6 (85.7) 0.64
Suicide attempts in the past, n (%) 12 (92.3) 5 (71.4) 0.21
CTQ, total score (±SEM) 74.0 (±5.1) 38.1 (±1.0) <0.001
Emotional abuse 18.1 (±1.5) 9.7 (±0.7) <0.001
Physical abuse 14.2 (±1.6) 6.1 (±0.6) <0.001
Sexual abuse 11.5 (±2.1) 5.1 (±0.1) 0.01
Emotional neglect 17.0 (±1.3) 11.0 (±1.1) <0.01
Physical neglect 13.4 (±1.2) 6.1 (±0.5) <0.001
HAM-D21 score (±SEM) 28.6 (±1.5) 25.2 (±1.9) 0.20
SEM, standard error of mean; NS, non-significant; CTQ, Childhood Trauma Questionnaire; HAM-D21, Hamilton Depression Rating Scale.
Moreover, we calculated the CAR, measured using the
AUCg(0–30′–60′). Depressed patients and controls did not dif-
fer significantly in the CAR both after placebo (33.7± 3.6
vs. 40.0± 3.9 nmol× h/L; p= 0.36) and after dexamethasone
(3.4± 0.6 vs. 2.5± 0.5 nmol× h/L; p= 0.39). However, depressed
patients showed a significantly lower CAR after fludrocortisone
compared with controls (21.0± 3.1 vs. 32.3± 4.4 nmol× h/L;
p= 0.04). In summary, these results showed that depressed
patients have higher suppression by fludrocortisone, a MR agonist,
but a similar suppression by dexamethasone, a GR agonist,
compared to controls (Figure 2).
When comparing depressed patients with ELS vs. without
ELS vs. controls, the GLM analysis did not show a main effect
of groups (F = 1.31; df= 2.0; p= 0.28), nor a group× time
interaction (F = 0.79; df= 8.0; p= 0.61), but showed a main
effect of time (F = 19.5; df= 4.0; p< 0.001). The GLM analy-
sis also showed a main effect of challenge (F = 92.8; df= 2.0;
p< 0.001) and a challenge× time interaction (F = 14.4; df= 8.0;
p< 0.001). Subsequent pairwise analysis indicated that there
was a difference between placebo and fludrocortisone in their
effects on salivary cortisol (p= 0.002), between placebo and
dexamethasone (p< 0.001), and between fludrocortisone and
dexamethasone (p< 0.001). The GLM analysis did not show
a significant group× challenge interaction (F = 1.88; df= 4.0;
p= 0.12) and a group× challenge× time interaction (F = 1.09;
df= 16.0; p= 0.39).
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According to ANOVA, there was no significant difference in
the CAR among depressed patients with ELS, without ELS, and
controls after placebo (F = 0.99; df= 2.0; p= 0.38), after dexam-
ethasone (F = 1.54; df= 2.0; p= 0.23), and after fludrocortisone
(F = 2.28; df= 2.0; p= 0.12). However, upon separately evalu-
ating the CAR in patients with ELS, without ELS, and controls,
we found that the effects of dexamethasone and fludrocortisone
were different. In controls, we found significant differences in
the CAR between placebo and dexamethasone (p< 0.001) and
between dexamethasone and fludrocortisone (p< 0.001), but no
difference between placebo and fludrocortisone (p= 0.25), indi-
cating suppression of salivary cortisol by GR agonist, but not
by MR agonist in controls. In patients without ELS, there were
significant differences in the CAR between placebo and dexam-
ethasone (p= 0.004). There were no differences between placebo
FIGURE 2 | Cortisol awakening response (measured as area under the
curve) after placebo, dexamethasone (GR agonist), and fludrocortisone
(MR agonist) in 20 depressed patients and 10 healthy controls;
*p<0.05. Note: AUCg(0–30′–60′ ) =Area under the curve from salivary cortisol
immediately upon awakening, 30 and 60 min later (nmol×h/L); values are
means, with standard errors represented by vertical bars.
and fludrocortisone (p= 0.24) or between dexamethasone and
fludrocortisone (p= 0.12). These data indicate that, as well as
in controls, patients without ELS suppress salivary cortisol only
by GR agonist. The situation in depressed patients with ELS was
different. There were significant differences in the CAR between
placebo and dexamethasone (p< 0.001), between placebo and flu-
drocortisone (p= 0.02), and between dexamethasone and fludro-
cortisone (p= 0.001), indicating suppression of salivary cortisol
by both GR and MR agonists in patients with ELS (Figure 3).
With respect to the plasma cortisol at 9:00 a.m., there
was no significant difference between depressed patients with
ELS, without ELS, and controls after placebo (459.7± 43.2
vs. 446.2± 71.0 vs. 437.0± 61.3 nmol/L; F = 0.04; df= 2.0;
p= 0.95), after dexamethasone (54.9± 6.5 vs. 101.3± 34.4 vs.
77.5± 27.1 nmol/L; F = 1.10; df= 2.0; p= 0.34), and after fludro-
cortisone (384.7± 55.2 vs. 363.0± 55.4 vs. 324.2± 29.4 nmol/L;
F = 0.41; df= 2.0; p= 0.66). Finally, we correlated the plasma cor-
tisol levels after placebo and CTQ scores in the depressed patients
and controls. Interestingly, there was a highly positive correlation
between plasma cortisol and the severity of ELS in patients with
ELS (R= 0.66; p= 0.01). No correlation was found in patients
without ELS (R=−0.54; p= 0.20) and in controls (R= 0.48;
p= 0.16).
The objective of the present study was to evaluate the impact of
the severity of CTQ scores on, MR and GR in depressive patients
with and without ELS for which a multiple regression analysis was
conducted. Using CTQ scores as a continuous variable HAM-D21,
and cortisol measures (CAR after placebo, dexamethasone, flu-
drocortisone) and BMI we found in a Linear Regression model in
depressive patients with ELS: R= 0.89; ∆R2= 0.79; ∆F = 5.31;
df= 5; and p= 0.025; and in depressive without ELS R= 1.0;
∆R2= 1.0; ∆F = 739.25; df= 5; and p= 0.028. In this model,
the correlation between CTQ, HAM-D21, BMI, CAR (measured
as AUC) after placebo, dexamethasone, and fludrocortisone keeps
the importance of MR in depressed patients with ELS, but not
GR: a significant positive correlation between AUC placebo vs.
FIGURE 3 | Cortisol awakening response (measured as area under
the curve) after placebo, dexamethasone (GR agonist), and
fludrocortisone (MR agonist) in (A) depressed patients without early
life stress (n=7); placebo vs. dexamethasone **p<0.01 and (B)
depressed patients with early life stress (n=13); placebo vs.
fludrocortisone *p=0.02; placebo vs. dexamethasone, and
dexamethasone vs. fludrocortisone ***p≤0.001. Note:
AUCg(0–30′–60′ ) =Area under the curve from salivary cortisol immediately
upon awakening, 30 and 60 min later (nmol×h/L); values are means, with
standard errors represented by vertical bars.
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Table 2 | Cortisol awakening response (measured as area under the curve) after placebo, dexamethasone, and fludrocortisone in depressed
patients with or without early life stress and controls; and adjusting for CTQ scores, BMI, and HAMD-21.
Mean (SEM) AUC placebo AUC dexamethasone AUC fludrocortisone p p Adjusted
With ELS 36.0 (±4.2) 2.8 (±0.4)*# 22.4 (±4.4)¶ <0.001 0.025
Without ELS 29.6 (±6.9) 4.5 (±1.6)** 18.4 (±3.8) 0.005 0.028
Controls 40.0 (±3.9) 2.5 (±0.5)## 32.3 (±4.4)¶¶ <0.001 0.366
ELS, early life stress; AUC, area under the curve from salivary cortisol immediately upon awakening, 30 and 60 min later (nmol×h/L); SEM, standard error of mean.
CTQ, Childhood Trauma Questionnaire; HAM-D21, Hamilton Depression Rating Scale. p, Pearson correlation. BMI, body mass index.
In depressed patients with ELS: *p<0.001 placebo vs. dexamethasone, #p=0.001 dexamethasone vs. fludrocortisone, ¶p= 0.02 placebo vs. fludrocortisone.
In patients with depression without ELS: **p=0.004 placebo vs. dexamethasone.
In controls: ##p< 0.001 placebo vs. dexamethasone, ¶¶p<0.001 placebo vs. fludrocortisone.
Adjusting for CTQ scores, BMI and HAM-D21
In patients with depression with ELS: p<0.05 placebo vs. fludrocortisone, p<0.01 fludrocortisone vs. dexamethasone.
In patients with depression without ELS: p<0.05 placebo vs. fludrocortisone, p< 0.05 placebo vs. dexamethasone, p<0.01 fludrocortisone vs. dexamethasone.
Table 3 | Pearson correlation between CTQ, HAM-D21, BMI, cortisol awakening response (measured as AUC) after placebo, dexamethasone and
fludrocortisone in a linear regression model in depressive patients with early life stress (ELS) and without ELS.
Mean (SEM) CTQ AUC placebo AUC dexamethasone AUC fludrocortisone HAMD BMI
WITH ELS
CTQ 1 0.13 −0.34 −0.15 0.43 −0.84**
AUC placebo 0.13 1 0.11 0.51* 0.41 −0.03
AUC dexamethasone −0.34 0.11 1 0.76** −0.31 0.20
AUC fludrocortisone −0.15 0.51* 0.76** 1 −0.05 0.18
HAMD 0.43 0.41 −0.31 −0.05 1 −0.40
BMI −0.84** −0.03 0.20 0.18 −0.40 1
WITHOUT ELS
CTQ 1 −0.34 −0.78* −0.72* −0.36 0.21
AUC placebo −0.34 1 0.53* 0.69* −0.35 0.19
AUC dexamethasone −0.78* 0.53* 1 0.70* −0.26 0.08
AUC fludrocortisone −0.72* 0.69* 0.70* 1 0.15 −0.22
HAMD −0.36 −0.35 −0.26 0.15 1 −0.49
BMI 0.21 0.19 0.08 −0.22 −0.49 1
ELS, early life stress; AUC, area under the curve from salivary cortisol immediately upon awakening, 30 and 60 min later (nmol×h/L); CTQ: Childhood Trauma
Questionnaire; HAM-D21, Hamilton Depression Rating Scale. R, Pearson correlation. BMI, body mass index. *p≤0.05; **p≤0.01.
AUC fludrocortisone (R= 0.51; p< 0.05); AUC fludrocortisone
vs. AUC dexamethasone (R= 0.76; p< 0.01) and a negative sig-
nificant correlation between scores of CTQ and BMI (R=−0.84;
p< 0.01). We could not find correlation between AUC placebo vs.
AUC dexamethasone (R= 0.11; NS) and in the others measures
included in the model, see details in Tables 2 and 3.
In patients with depression without ELS, on the other hand we
found significant correlation between GR and MR agonists and
placebo: a significant positive correlation between AUC placebo
vs. AUC fludrocortisone (R= 0.69; p< 0.05); AUC placebo vs.
AUC dexamethasone (R= 0.53; p< 0.05); AUC fludrocortisone
vs. AUC dexamethasone (R= 0.70; p< 0.01) and a negative sig-
nificant correlation between CTQ scores vs. AUC dexamethasone
(R=−0.78; p< 0.01) and CTQ scores vs. AUC fludrocortisone
(R=−0.72; p< 0.01), see details in Tables 2 and 3. In healthy
controls R= 0.80; ∆R2= 0.20; ∆F = 5.82; df= 5; and p= 0.366;
a significant positive correlation between AUC placebo vs. AUC
fludrocortisone (R= 0.69; p< 0.05); AUC fludrocortisone vs.
AUC dexamethasone (R= 0.66; p< 0.05).
DISCUSSION
This study was designed to clarify the status of the impact of ELS
in HPA axis response to challenges with GR and MR agonist in
depressed patients. We included patients with current depressive
episode (Hamilton Rating Scale ≥17) with ELS (65%) and with-
out ELS (35%). Cortisol measures in the saliva and plasma were
evaluated after MR or GR agonist. Firstly, we examined the cortisol
in depressed patients and healthy controls. Our data demonstrate
that in our sample, depressed patients, with high incidence of ELS
(65%) and suicide attempts (85%), had significantly lower levels
of salivary cortisol compared to control subjects upon waking after
placebo.
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Our results are consistent with other studies that show low
cortisol levels associated with several stress neuropsychiatric
disorders, such as posttraumatic stress disorder (PTSD), chronic
pain, fibromyalgia/fatigue syndromes, and atypical depression
(72–75). Low levels of cortisol have also been demonstrated in
depressed trauma survivors (55) and childhood sexual abuse vic-
tims (76). In this regard, an important link between trauma
and atypical depression comes from studies that exhibit down-
regulation of HPA axis due to chronic stress. Some authors have
called attention to the role of HPA axis in the etiology of different
subtypes of depression. The atypical depression has been asso-
ciated in some studies with higher rates of neglect/child abuse,
family alcohol/drug disorder, high rates of psychiatric comorbidi-
ties, and chronicity of depression (77–80). Several studies have
also demonstrated a hypoactivity of the HPA axis, a lower activ-
ity of CRH, hypocortisolism, and a decrease in activity of afferent
noradrenergic pathways in depression with atypical features (73,
81, 82). In contrast, melancholic depression has been associated
with a lower incidence of stressful events, lower rates of personality
disorders, a lower incidence of suicide attempts, and a hyperactive
of the HPA axis (79, 83–85). In this sense, our findings are in
line with prior studies, where a pattern of HPA axis hypofunction
and reduced secretion of CRH, mediated by an increased negative
feedback, appear to be present in depressed patients evaluated in
our study (73, 81).
Our results also demonstrate that depressed patients showed a
significantly lower CAR after fludrocortisone, but not after dexam-
ethasone compared with healthy controls. These data demonstrate
that depressed patients have higher suppression of HPA axis in
response to the MR agonist (fludrocortisone), but a similar sup-
pression by GR agonist (dexamethasone), compared to healthy
control subjects. Thus, our findings indicate the possibility of an
imbalance between GR and MR, with increased MR activity in
depressed patients compared with controls.
Although studies of literature have proved the importance of
MR in depression, the results about the role of MR in depres-
sion are inconsistent. While some studies, ours included, showed
increased MR activity, other studies showed that MR function is
reduced in depression. MR function can be assessed by MR antag-
onist (spironolactone), this compound is able to activate the HPA
axis blocking MR mediated negative feedback. Young et al. (52)
showed a significant increase in cortisol levels in patients treated
with spironolactone. Based on these data, the authors suggest that
MR activity is increased in patients with depression compared
with controls and that the depression is accompanied by a shift
in the balance between GR and MR (52). Furthermore, studies
have demonstrated in depressed patients an up-regulated MR gene
expression in the hypothalamus (86), down-regulation of hip-
pocampal MR in response to antidepressants (87), and reduced
residual symptoms in euthymic patients with bipolar disorder
(88), suggesting that blocking MR might be promising from a ther-
apeutic perspective. On the other hand, Otte et al. (50) examined
the response to antidepressants through stimulation and blockade
of MR and found decreased plasma cortisol levels in depressed
patients treated with fludrocortisone as adjunct to escitalopram
and that the stimulation of MR with fludrocortisone acceler-
ated the response to treatment. Furthermore, the combination
of spironolactone and escitalopram increased plasma cortisol lev-
els during treatment (50). There are also studies that suggest that
depressed suicide victims showed decreased MR messenger RNA
in the hippocampus compared with healthy controls (89). Recently
Lembke et al. (49) published a study showing that individuals with
PMD compared to healthy control subjects have diminished feed-
back inhibition of the HPA axis in response to the MR agonist
fludrocortisone (49). Our group recently published (60) a study
with treatment-resistant depression (TRD) patients showing that
TRD had higher cortisol compared with controls after (a) the
effect of combined GR/MR stimulation with prednisolone; (b)
the effect of prednisolone with the MR antagonist spironolactone;
and (c) the effect of spironolactone alone. In healthy controls,
spironolactone increased cortisol compared to placebo. The co-
administration of spironolactone with prednisolone in controls
decreases the suppressive effects of prednisolone. In contrast, in
TRD,spironolactone did not increase cortisol compared to placebo
and spironolactone with prednisolone had no effect on the sup-
pressive effects of prednisolone. Our data confirmed that TRD
is associated with hypercortisolism and these patients no longer
show an HPA axis response to the administration of a MR antag-
onist, suggesting that there is a MR malfunctioning, such as a
down-regulation (60). Therefore, these findings suggest that dys-
regulation of the HPA axis in depression is partially attributable to
an imbalance between GR and MR suggesting MR is a promising
approach to improve antidepressant treatment in TRD (60).
With regard to GR, there are several studies in the literature with
dexamethasone (alone or in combination with CRH) in depres-
sion. Most of them have shown an increased activity of the HPA
axis in depressive patients compared to healthy controls, associated
with hypercortisolemia and reduced inhibitory feedback. These
findings suggest that GR function is impaired in major depres-
sion, resulting in reduced GR-mediated negative feedback on the
HPA axis (34, 41–43, 90, 91). In contrast, in our study, as well
as the study of Vreeburg et al. (24) and Gervasoni et al. (92), we
did not find cortisol non-suppression by GR agonist (dexametha-
sone) in the depressed groups. However, most studies that found
more non-suppression after dexamethasone among depressed
subjects were conducted among more severely depressed patients
with melancholic, psychotic, or bipolar depression (43, 91, 93),
unlike our sample that consisted predominantly of patients with
unipolar depression and ELS. Furthermore, studies have demon-
strated that psychotic depression was most clearly associated with
prominent non-suppression, whereas the non-suppression rate in
non-melancholic was low (73, 74, 81–83, 85).
Concerning the evaluation of impact of ELS in HPA axis
response to challenges with GR and MR agonist in depression,
our findings indicate that patients with ELS show suppression of
salivary cortisol levels after fludrocortisone (MR agonist) and dex-
amethasone (GR agonist), indicating that patients with ELS are
equally sensitive to both GR and MR. In contrast, in depressed
patients without ELS and controls, such suppression after flu-
drocortisone was not found. Patients without ELS and controls
showed only suppression by dexamethasone.
However, when we control the data for depression scores
(HAMD), BMI and use CTQ scores as continuous measures
correlating with CAR AUC (nmol× h/L) after placebo vs.
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fludrocortisone vs. dexamethasone, the data retain the differ-
ences for ELS between after fludrocortisone (MR agonist) but not
after dexamethasone (GR agonist), in the same line for depres-
sive patients without ELS the data retain the differences for ELS
between after fludrocortisone (MR agonist) but now as well as
after dexamethasone (GR agonist). This data may suggest that
controlling depression scores, CTQ scores measures the higher
severity of childhood trauma and depressive symptoms increase
the MR malfunction (60). Thus, our data indicate differences in
the functioning of the HPA axis between depressed patients with
and without ELS and suggest that patients with ELS are more sen-
sitive to MR agonist than patients without ELS. Therefore, these
findings suggest that ELS could be fundamental to impairment of
MR function, as found in our study.
Although studies are still restricted, it seems a consensus that
ELS is associated with modification of the HPA axis in the first
stages of life, which leads to a biological vulnerability to devel-
oping depression in adulthood (15, 58, 94). Since the HPA axis is
activated in response to stressors, early life stressful events may also
have an etiologically significant role in the HPA axis abnormalities
found in depression. Increasing evidence indicates that childhood
neglect and abuse are risk factors for adult onset depression (14).
It has been concluded from these studies that ELS may lead to
disruptions in HPA axis functioning and that factors such as age
of maltreatment, parental responsiveness, subsequent exposure to
stressors, type of ELS, and type of psychopathology or behavioral
disturbance displayed may influence the degree and pattern of
HPA disturbance (14, 95). Although, there is consensus in the lit-
erature that ELS is associated with modification of the HPA axis,
the data about the functioning of GR and MR in subjects with
ELS are still limited and most studies assess only GR function (8,
55, 57, 58). In this sense, genetics studies in rodents have shown
that ELS has epigenomic effects by altering DNA methylation of
the GR gene promoter in the hippocampus, leading to functional
impairment of the GR and consequently impaired feedback regu-
lation and increased stress responsiveness (96). Still about the role
of the ELS in GR, the results of studies with neuroendocrine tests
are inconsistent. While, the studies of Heim et al. (8) with abused
men with current major depression and Tyrka et al. (57) with
healthy adults with parental loss during childhood showed non-
suppression by Dex/CRH test, suggesting a decrease of GR activity
in subjects with ELS. On the other hand, the study of Newport
et al. (55) suggests increased GR activity in women with a history
of child abuse and major depression. Moreover, no studies were
found in the literature evaluating the role of the ELS specifically in
the MR functioning. Thus, because depression is associated with
an imbalance between GR and MR (15, 32, 34–36) and based on
the data of the literature that demonstrate the influence of ELS
in the GR and MR functioning (8, 55, 57). We also conducted
separate analyses in depressed patients with and without ELS, in
addition to the analysis performed between groups vs. challenge,
in order to better investigate our hypothesis that the ELS results
in a persistent dysfunction of GR/MR receptors, leading to MR
malfunction, in adulthood depressive patient.
Several limitations of the current study should be considered.
First, the sample size was relatively small, particularly the sub-
group of depressed patients without ELS that reduces the statistical
power of our results. Therefore, it is important that our results be
interpreted with caution given the sample size. However, despite
the limitation of size of our sample and lack of statistical power
of our results, according to our knowledge to date, this is the
first study published with neuroendocrine challenges that specif-
ically evaluate the functioning of MR in depressive patients with
ELS. Second, is the reliance on retrospective self-report question-
naire for investigation of ELS, as the CTQ, used in our study,
which is subject to simple forgetting and reporting biases due
to mood state of the patient. Third, we did not apply specific
instruments to describe our sample with regard to subtypes of
melancholic and atypical depression, which could contribute to
a better understanding of our neuroendocrine findings. Another
potential confounder for our study is that we did not characterize
our sample with respect to depressive episodes with or without
psychotic features and number of previous depressive episodes,
which can influence our biological outcomes. In addition, all our
patients were taking antidepressant, which also may have affected
the results. Although, this is possible, Kunugi et al. (91) demon-
strated that hormonal measures did not differ between patients
receiving medication and patients without medication on admis-
sion, indicating that medication status did not affect Dex/CRH test
results (91). This observation is in line with the finding that the
presence or absence of antidepressant treatment and the type and
number of antidepressant treatments during the index episode
had no effect on hormonal responses to the Dex/CRH test (97).
It might also be useful to allow comparison of male and female
subjects to ascertain, whether sex steroids and menopausal sta-
tus can influence HPA axis dysfunction and other hormones like
ACTH and aldosterone, the most selective hormone to bind to MR,
which could be measured concomitantly to improve the overall
assessment of MR sensitivity and function (30). Another limita-
tion in our study is that we evaluated the HPA axis response to
challenges with dexamethasone and fludrocortisone and assume
that the observed HPA axis suppression is predominantly due
to dexamethasone binding at GR, but dexamethasone can also
bind to MR and that suppression is predominantly due to flu-
drocortisone binding at MR, but fludrocortisone can also bind
to GR. Indeed, it is possible that fludrocortisone effect might be
due in part to minor effects on GR and dexamethasone on MR.
Thus, as well as depression needs to be further investigated as
to the role of MR receptors in regulating the inhibitory feed-
back of the HPA axis, changes that ELS generates in the HPA
axis need further elucidation (98). Therefore, future studies with
larger samples and longitudinal designs to assess the influence
of ELS in treatment response with tests that assess both GR
and MR, such as prednisolone (a mixed agonist GR/MR), are
needed.
CONCLUSION
According to our knowledge to date, this is the first study to eval-
uate HPA axis response to MR stimulation in depressive patients
with and without ELS. Our findings indicate that MR activity is
increased in depressed patients compared with controls. Further-
more, in spite of the previous limitations described, in depressed
patients with ELS, controlling severity of depression, childhood
trauma, and BMI there was suppression by fludrocortisone,
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indicating that patients with ELS are sensitive to MR agonists.
In contrast, we find suppression in depressed patients without
ELS after both MR and GR agonist. These data could suggest that
patients with ELS could be more sensitive to MR agonist than
patients without ELS and that ELS could trigger changes in MR
activity, but not in GR that might explain the occurrence of distinct
results in the subgroups of depression.
However, for better understanding the mechanism by which
exposure to ELS leads to such impairment in depression, future
studies with larger samples and longitudinal designs ideally should
also consider the Environment vs. Gene interaction model. There-
fore, once we confirm these data we may develop approaches
to early intervention, including new pharmacologic targets and
psychoeducational strategies, among others.
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